Pharmaceutical News

RSS

Watson Pharmaceuticals first-quarter net revenue up 28% to $856.5M

Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.

10 May 2010

Healing Arts Cooperative Medical Marijuana to open new location in San Diego

International Merchant Advisors, Inc. announced today that the company's client, Healing Arts Cooperative Medical Marijuana is opening a new location in San Diego. IMAI has previously signed a management agreement to operate all of the Healing Arts Cooperative Medical Marijuana dispensaries and to operate the cooperative as the manager of the facility on behalf of its non profit owners. Healing Arts is a cash flow generating non profit, fulfilling the needs of medical marijuana patients in California and planning further expansion in the state.

10 May 2010

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

Cipher Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults.

10 May 2010

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the first quarter ended March 31, 2010.

10 May 2010

Drug study results, interpretation favour wishes of sponsor pharmaceutical companies

Drug studies financed by pharmaceutical companies frequently show positive results in favour of the sponsor. In the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107(16): 279-85), a research group headed by the Chairman of the Drug Commission of the German Medical Association, Prof. Wolf-Dieter Ludwig, describes the influence of sponsoring on the results, protocol and quality of drugs studies.

10 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

GSK participates in FDA advisory committee's rotavirus vaccine meeting

GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.

10 May 2010

Evotec and Genentech sign drug discovery deal

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group (SWX:RO) (SIX:ROG) (Pink Sheets:RHHBY), to discover novel small molecule therapeutics.

10 May 2010

Steroids can raise cardiovascular risks in post-transplant patients

Post-transplant patients who have been removed from a corticosteroid regimen have fewer cardiovascular events than those patients on steroids, increasing their graft survival rates and reducing early mortality, according to study results being presented this week by University of Cincinnati (UC) transplantation researchers.

10 May 2010

Scientists develop dry, inhalable measles vaccine, will begin testing in India this summer

CBSNews.com reports on the development of a dry, inhalable measles vaccine by researchers at the University of Colorado-Boulder (CU-Boulder), who hope that their work will "help pave the way for the inexpensive treatment of a range of other illnesses" (Cooper, 5/5).

10 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

Watson Pharmaceuticals reaches patent litigation settlement with Teva Women's Health

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

10 May 2010

House committee to investigate Johnson & Johnson after kids' Tylenol recall

A House committee is looking at Johnson & Johnson after the company announced a recall of children's medicines. "Lawmakers requested information on Thursday from regulators about Johnson & Johnson's recall of Children's Tylenol and other over-the-counter pediatric medicines, saying the company's repeated recalls 'point to a major problem' with production," Reuters/The New York Times reports.

10 May 2010

Swedish scientists discover a new method to develop effective antimalarial drugs

Amodiaquine was introduced as an antimalarial drug, but was withdrawn when serious adverse effects were observed. Scientists at the University of Gothenburg, Sweden, have now developed a method that can be used to develop safer drugs.

10 May 2010

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.

7 May 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

NPWH launches ETIQ campaign to improve access to information about menopause, estrogen therapy

The National Association of Nurse Practitioners in Women's Health announced the launch of Estrogen Therapy I.Q. a campaign devoted to improving access to credible information about menopause and advances in estrogen therapy.

7 May 2010

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the first quarter ended March 31, 2010. The Company also highlighted key commercial and regulatory progress during the quarter, and provided its expected milestones for the remainder of 2010.

7 May 2010

New changes to 'Extra Help' program enables more people save on prescription drug costs

Medicare beneficiaries who qualify for "Extra Help" may be eligible to pay no more than $2.50 for generic drugs and $6.30 for each brand name drug thanks to changes to Medicare's Low-Income Subsidy Program for Part D prescription drug costs (also known as LIS or "Extra Help") that take effect this year. These changes make it easier than ever for people on Medicare with limited incomes to save on their drug costs.

7 May 2010

Pharmaceutical News

Watson Pharmaceuticals first-quarter net revenue up 28% to $856.5M

Healing Arts Cooperative Medical Marijuana to open new location in San Diego

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

Drug study results, interpretation favour wishes of sponsor pharmaceutical companies

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

GSK participates in FDA advisory committee's rotavirus vaccine meeting

Evotec and Genentech sign drug discovery deal

Steroids can raise cardiovascular risks in post-transplant patients

Scientists develop dry, inhalable measles vaccine, will begin testing in India this summer

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Watson Pharmaceuticals reaches patent litigation settlement with Teva Women's Health

House committee to investigate Johnson & Johnson after kids' Tylenol recall

Swedish scientists discover a new method to develop effective antimalarial drugs

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

NPWH launches ETIQ campaign to improve access to information about menopause, estrogen therapy

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

New changes to 'Extra Help' program enables more people save on prescription drug costs

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News